IDEXX Laboratories, Inc.

NASDAQ:IDXX

Medical - Diagnostics & Research

Healthcare
$698.47 +2.26%

+$12.33 today

Market cap
$55.03B
Beta
1.54
P/E (TTM)
40.8
EPS (TTM)
$13.67
52W Low $506.91High $769.98

Volume 0.37M

Average 0.58M

IDXX Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

IDEXX Laboratories, Inc.NASDAQ: IDXX

Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026

Capital expenditures declines year over year

Q3 FY2026 capital expenditures of $28.93M (cash outflow) fell 7.0% year over year, ahead of the -14.5% change in trailing-twelve-month capital expenditures. Sequentially, it rose 17.4% from the prior quarter. Over 3 fiscal years it compounded at -5.7% a year.

Context

  • Capital expenditures amounted to 2.9% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -7.0% holds above the trailing-twelve-month pace of -14.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$28.93M+17.4% QoQ
Last fiscal yearDec 2025
-$124.68M-4.8% YoY
LTMSep 2026
-$114.99M-14.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.0%——
1 year-4.8%——
3-year CAGR-5.7%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(124.68M) USD
Year-over-year change
+4.8%

Capital Expenditures vs competitors

How IDXX compares with its peers on the latest reported figures

  • IDXX's LTM Sep 2026 capital expenditures of $114.99M is the 4th largest of the 5 companies compared; the peer median is $363.5M.
  • Its year-over-year change of -14.5% is the 2nd highest of 5, against a peer median of -24.7%.
  • Capital expenditures amounts to 2.5% of revenue for IDXX, versus a peer median of 4.7%.
IDXX Competitors Peer median
Capital Expenditures for IDXX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$3.9B +2.4%-2.1%5.9%
ZTSZoetis Inc.LTM Jun 2026$521M -26.6%+2.0%5.5%
ELANElanco Animal Health IncorporatedLTM Sep 2026$206M -22.8%+14.5%4.0%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$114.99M -14.5%-5.7%2.5%
NEOGNeogen CorporationLTM Aug 2026$35.5M -60.6%-7.9%4.0%
Peer median (excluding IDXX) $363.5M-24.7%-0.1%4.7%

Competitors are the stored peer set for IDXX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income744.84M679.09M845.04M887.87M1.06B
Depreciation & Amortization104.6M111.9M114.91M129.94M145.18M
Deferred Income Tax(3.38M)(35.07M)(48.31M)(24.19M)131.2M
Stock-Based Compensation37.76M49.77M59.74M60.3M0
Change in Working Capital(137.52M)(273.53M)(72.43M)(133.24M)(227.51M)
Accounts Receivables(33.14M)(41.4M)(53.87M)(28.28M)(68.72M)
Inventory(52.92M)(121.73M)(28.65M)(28M)(789K)
Accounts Payables11.23M3.47M(557K)8.09M(8.57M)
Other Working Capital(62.7M)(113.87M)10.65M(85.04M)(149.43M)
Other Non-Cash Items9.25M10.82M7.56M8.34M69.73M
Operating Cash Flow755.55M542.98M906.51M929M1.18B
Capital Expenditures(119.55M)(148.84M)(133.63M)(130.92M)(124.68M)
Acquisitions (Net)(173.42M)(46.51M)0(77.7M)0
Purchases of Investments0(25M)00(756K)
Sales of Investments071.51M01.56M0
Other Investing Activities0(46.51M)8.38M(10M)2.74M
Investing Cash Flow(292.97M)(195.35M)(125.25M)(207.06M)(136.24M)
Debt Repayment23.5M430.5M(404M)(75M)(30.39M)
Common Stock Issued46.57M35.75M47.03M44.49M93.36M
Common Stock Repurchased(746.78M)(819.71M)(71.92M)(837.03M)(1.22B)
Dividends Paid00000
Other Financing Activities(20.7M)(17.04M)(13.11M)(10.53M)(7.24M)
Financing Cash Flow(697.41M)(370.94M)(442M)(878.07M)(1.16B)
Effect of Forex Changes(4.64M)(8.61M)2.13M(9.53M)11.2M
Net Change in Cash(239.47M)(31.91M)341.39M(165.67M)(108.2M)
Free Cash Flow636M394.15M772.88M798.08M1.05B

IDEXX Laboratories, Inc.

NASDAQ:IDXX

Intrinsic Alpha fair value

Locked

Current Price

$698.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.